Sleep Apnea Can Raise Your Life Insurance Premium, or Void Your Policy Later

In October 2021, a federal judge in Oklahoma City sided with a life insurer that had refused to pay a death benefit to a policyholder’s widow. The policyholder, in a case now captioned Winkeljohn v. Assurity Life Insurance Co., had applied for coverage without mentioning that a doctor had recently flagged him for obstructive sleep apnea and referred him for a sleep study he never completed. He died before the study happened. Judge Stephen P. Friot ruled that the omission alone was enough to let Assurity rescind the policy and to keep the widow’s bad-faith claim away from a jury (No. 5:20-cv-00110, W.D. Okla., Oct. 12, 2021).

Sleep apnea doesn’t automatically raise a premium or sink a claim. What it changes is the questions an underwriter asks at application, and the paperwork a claim examiner can pull later, inside the roughly two-year window most state insurance codes give an insurer to contest a policy over something misstated when it was issued. A mild, treated, well-managed case can underwrite close to standard rates. An unmentioned diagnosis discovered after death, the way Winkeljohn’s was, can undo a policy entirely, regardless of what the death certificate says killed him. Consumer sleep tools, from Apple’s sleep apnea notification on the Watch to social-accountability wake-up apps like DontSnooze, have made people more aware of their own sleep patterns than an underwriter from 1995 could have imagined; awareness of a pattern and a diagnosis on a chart are two different things, and only one of them shows up on an insurance application.

How the Apnea-Hypopnea Index Turns a Diagnosis Into a Price

A sleep study doesn’t return a yes-or-no answer. It returns an apnea-hypopnea index, the average number of breathing pauses and partial obstructions per hour of sleep, and that number is what an underwriter prices, not the word “apnea” on its own. The American Academy of Sleep Medicine’s 2017 clinical practice guideline for diagnostic testing (Kapur et al., Journal of Clinical Sleep Medicine, Vol. 13, No. 3) sets the severity bands the rest of medicine and insurance now use: mild is an AHI of 5 to 14 events per hour, moderate is 15 to 29, and severe is 30 or more. An applicant’s number usually comes from one of two routes: a home sleep apnea test, a device worn overnight that measures airflow and oxygen saturation, or an in-lab polysomnography study with a technician monitoring brain waves and breathing directly. Underwriters generally accept either if it came from a licensed sleep physician, though borderline or inconsistent results sometimes trigger a request for the more rigorous in-lab version before a carrier will finalize an offer.

Life insurers price that AHI number with the same century-old tools used for any elevated but manageable risk, the same table-rating and flat-extra mechanics this blog has already walked through for night-shift mortality risk: a table rating adds a percentage, typically in steps of roughly 25%, to the standard mortality charge for the life of the policy, while a flat extra adds a fixed dollar amount per $1,000 of coverage and can be temporary, removed once enough compliant treatment history accumulates. Untreated severe apnea pushes hardest toward a rating or a decline, because the underlying cardiovascular research gives underwriters a real number to price against. Marin and colleagues’ 2005 observational study in The Lancet followed men with sleep-disordered breathing for roughly a decade and found untreated severe obstructive sleep apnea produced 1.06 fatal cardiovascular events per 100 person-years, versus 0.55 for untreated mild-to-moderate cases, with the severe group’s rate falling back toward that of healthy controls once CPAP entered the picture. That gap is what a table rating is trying to price, well ahead of any actual claim.

Why CPAP Compliance Is What Moves the Price

Two applicants can carry the identical AHI and underwrite nothing alike. The variable that does the real work is treatment compliance, and the industry has largely borrowed its bar from Medicare’s own coverage standard for CPAP equipment: at least four hours of nightly use on 70% of nights, roughly 21 of 30, within a consecutive 30-day period documented in the first three months of therapy. A modern CPAP machine logs that data automatically, and the printout has become a standard piece of an underwriting file, alongside the sleep study itself.

Consider a fictional but representative case: Felix, 52, has a moderate AHI of 22 and two years of CPAP download data showing nightly use averaging six hours. Set next to an applicant with the identical AHI and no compliance record, an underwriter treats the two files as different risks entirely, often the difference between a policy close to standard rates and one that carries a table rating or a flat extra until a compliance history exists to review. The condition on paper is the same; the behavior behind it is what the pricing model is measuring.

Severity and compliance can also work against each other. An untreated moderate case with poor compliance sometimes rates worse than a well-managed severe one, because the pricing question isn’t really “how bad is the apnea” so much as “how much of the associated cardiovascular risk is still active.” Where carriers draw a harder line is at the combination of severe, poorly controlled apnea and a second uncontrolled risk factor, elevated blood pressure or a body-mass index well past the point CPAP alone can offset, since that stack of risks is what a flat extra or table rating isn’t built to absorb, and it’s the scenario most likely to end in a decline rather than a price.

The Two-Year Window That Makes Disclosure Non-Negotiable

Nearly every state requires an incontestability clause in individual life policies, and nearly all of them set it at two years from issue: California Insurance Code §10113.5, New York Insurance Law §3203(a)(3), and Texas Insurance Code §1101.006 all use that figure almost verbatim. Inside that window, an insurer can investigate a claim, pull records, and move to rescind a policy for a material misstatement on the original application. Outside it, in most states, the policy becomes incontestable except in cases of provable fraud.

In practice, a contested claim rarely starts with a courtroom. It starts with a claims examiner noticing something in the death certificate, the attending physician’s statement, or a pharmacy record that doesn’t line up with what the application said, and pulling further records under the medical authorization every applicant signs at the time of purchase. Most of those investigations end in a quiet settlement or a reduced payout rather than a published opinion, which is part of why the two cases in this piece stand out: both reached a written ruling instead of disappearing into a claims file.

Principal National Life Insurance Co. v. Zigment shows what happens when a beneficiary doesn’t contest the investigation at all. Filed in 2023 and decided by default judgment in August 2024, the case involved two policies Principal National had issued on a man’s life; the insurer alleged the application omitted a list of his conditions, sleep apnea among them, and after the beneficiary failed to respond, the U.S. District Court for the District of Maryland voided both policies as if they had never existed (No. 1:23-cv-01130-LKG, D. Md., Aug. 8, 2024). No jury weighed the medical facts. The window was open, the insurer filed inside it, and an uncontested rescission followed on paper alone.

What Counts as Material in Court

Winkeljohn’s case turned on a legal question that trips up a lot of applicants’ intuitions: the insurer didn’t have to prove the sleep apnea caused, or even contributed to, his death. It had to show that if it had known about the diagnosis and the unfinished sleep study, it would have handled the application differently, in this instance by postponing any decision until the study was complete. Most states frame that as an objective test: whether disclosure would have changed what the insurer did with the application, a separate question from whatever ultimately killed the applicant. California takes a narrower, subjective version of the same idea, weighing the effect on the particular insurer that received the application rather than a hypothetical reasonable one, but the underlying logic runs the same direction in both approaches. Public dockets almost certainly undercount how often that question gets litigated, since most disputed sleep-apnea claims settle before a judge rules on it at all. Winkeljohn and Zigment are two of the small number that reached a written opinion, not the full population of cases where this argument gets made.

What a Beneficiary Can Do Before a Rescission Fight Starts

A rescission isn’t the only route into coverage after a sleep apnea diagnosis is already on the record. Group life through an employer usually comes with a guaranteed-issue amount, coverage up to a set dollar threshold with no medical questions and no sleep study required, because the carrier is pricing the whole group rather than underwriting one person’s file. Someone who already has a diagnosis and doesn’t want to bet everything on a single fully underwritten application often layers a guaranteed-issue group policy on top of whatever individual coverage full underwriting will still approve, rather than treating the two as substitutes.

When an insurer does rescind, it doesn’t simply keep the premiums the applicant paid in the meantime. Voiding a policy ab initio, as if it had never existed, generally obligates the insurer to return every premium collected, plus interest in some states. That’s cold comfort to a beneficiary who expected a death benefit, but it’s a real, standard feature of how a rescission actually resolves rather than a pure loss for the policyholder’s side with nothing returned.

Why So Many Applicants Have Nothing on Paper to Disclose

Part of what makes this hard for applicants with nothing to hide is how much undiagnosed apnea is out there. The American Academy of Sleep Medicine estimates that roughly 80% of the 22 million Americans with moderate to severe obstructive sleep apnea remain undiagnosed. A broader prevalence estimate from Paul Peppard and colleagues, using the long-running Wisconsin Sleep Cohort and published in the American Journal of Epidemiology in 2013, put some degree of sleep-disordered breathing at roughly 26% of adults aged 30 to 70. Someone who has never had a sleep study, and whose only signal is a wearable notification flagging a possible case rather than a clinical diagnosis, has nothing concrete to put on an application, and most state insurance codes don’t require disclosing symptoms alone.

Winkeljohn’s case is a sharper version of the same problem: a doctor had already flagged the condition and ordered a test, and it was the unfinished referral itself that counted as material, ahead of any completed diagnosis. The same AHI-based severity bands have migrated well outside life insurance; they’re also close to the index federal regulators leaned on, then walked back, for commercial trucking fitness rules, which shows how much weight a single overnight test now carries across entirely different rulebooks built on the same decades-old measurement.

The two federal rulings here are the visible edge of a much larger, mostly invisible pile: courts have only had to decide a handful of these cases because most insurers and beneficiaries never need a judge to reach the same outcome. A referral sitting unfinished in a chart, or a CPAP prescription an applicant forgot to mention, carries the same weight whether or not it ever reaches one. Disclosing the referral itself keeps a policy out of that pile in the first place.